Landos’ unique core platform technology enables accelerated development of safer, more effective oral, first-in-class therapeutics for autoimmune diseases. Landos has identified Lanthionine Synthetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile.
landosbiopharma.com
landosbiopharma.com
Location: United States, Virginia, Blacksburg
Total raised: $86.7M
Investors 2
| Date | Name | Website |
| - | Perceptive... | perceptive... |
| - | Xontogeny | xontogeny.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.01.2023 | - | $16.7M | - |
| 13.08.2019 | Series B | $60M | Perceptive... |
| 22.09.2017 | Series A | $10M | Perceptive... |
Mentions in press and media 21
| Date | Title | Description |
| 15.01.2026 | This pharma stock just got whacked — there’s still a major catalyst ahead | - |
| 25.03.2024 | AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases | Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and La... |
| 25.03.2024 | AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition | AbbVie already has blockbuster drugs for ulcerative colitis, but that isn’t stopping the pharmaceutical giant from trying to expand its scope in this disease. To that end, the company is acquiring Landos Biopharma, a clinical-stage biotech ... |
| 05.01.2023 | Landos Biopharma Announces $16.7 Million Private Placement Financing | NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. LABP ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, toda... |
| 05.01.2023 | Landos Biopharma Provides Comprehensive Update on Clinical Development Plans | Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeli... |
| 05.01.2023 | Landos Biopharma Announces $16.7 Million Private Placement Financing | - |
| 24.06.2022 | After seven months of searching, Landos hires a CEO; Marty Duvall re-emerges from ill-fated Oncopeptides tenure | Gregory Oakes Landos Biopharma has landed a new CEO after seven months of being led by an interim chief executive. Gregory Oakes took the helm of the autoimmune biotech this month, bringing with him nearly 30 years of in... |
| 15.11.2021 | Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update | Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3... |
| 15.11.2021 | Landos Biopharma : Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Form 8-K | Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development ... |
| 20.08.2019 | Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT-11 in Mild to Moderate Ulcerative Colitis | – Global clinical trial underway in 11 countries, including U.S., European, and Eastern European sites to evaluate safety, efficacy and tolerability of orally administered, gut-restricted LANCL2 agonist BT-11, in patients with mild to moder... |
Show more